Chronic traumatic encephalopathy (CTE), which is common in athletes, is a progressive neurodegenerative disease and a long-term consequence of repetitive closed head injuries. CTE is regarded as a chronic brain syndrome due to the effects of repetitive traumatic brain injury (TBI). Because neurotrophic factors are neuroprotective in models of brain and spinal cord injuries, we examined the effects of cerebrolysin, a mixture of various neurotrophic factors, on brain pathology in a mouse model of repetitive mild TBI (rmTBI), which is a good model of CTE. Five groups were created and treated as follows: groups 1 and 2: rmTBI for 4 weeks following cerebrolysin injection for 4 weeks; groups 3 and 4: rmTBI for 8 weeks with or without cerebrolysin injection for 4 weeks; group 5: control. We found that p-tau expression was increased in the pyramidal layer of the cortex and hippocampus, particularly the CA3 region, but not in the CA1 region and the dentate gyrus (DG). Intra-tail vein administration of cerebrolysin (10 ml of 1 mg/ml) after/during rmTBI treatment reduced p-tau expression in both the cortex and hippocampus. Histological analysis revealed mild astrocyte activation (increased expression of glial fibrillary acidic protein (GFAP)) but not microglia activation (ionized calcium binding adaptor molecule 1 (iba-1) expression) and peripheral macrophage infiltration (CD45). Additionally, administration of cerebrolysin after rmTBI resulted in reduced astrocyte activation. These observations in rmTBI demonstrated that cerebrolysin treatment reduces phosphorylation of tau and astrocyte activation, attenuates brain pathology, and mitigates function deficits in TBI. Taken together, our observations suggest that cerebrolysin has potential therapeutic value in CTE.
Introduction
Chronic traumatic encephalopathy (CTE) has been defined as a progressive neurodegenerative disease caused by repetitive head trauma [20, 25] . CTE was first described in 1928 and has become a popular topic due to its close association with football, hockey, soccer, boxing, and professional wrestling injuries. Many of these affected athletes, mostly retired, have struggled in their later years with depression, substance abuse, anger, memory/motor disturbances, and suicide [17] . Autopsy results from these athletes have suggested a link between these emotional, cognitive, and physical manifestations and CTE [15] . Concussion or mild traumatic brain injury (rmTBI) is one of the most common neurologic disorders, accounting for approximately 90% of all brain injuries sustained [5] . However, rmTBI was underestimated or regarded as benign; in some, the injury was not recognized at all. In a 2009 review concerning CTE, McKee et al. found that 51 neuropathologically diagnosed cases of CTE 46 (90%) occurred in athletes [15] .
Repetitive concussive or subconcussive blows to the head have been recognized to place individuals at risk for CTE [6, 24] . However, no clear consensus exists regarding how much or little trauma is needed to cause CTE, while it is clear that anyone who experiences repetitive head trauma, regardless of the mechanism, is at risk of developing CTE.
In a study of repeated head trauma in mice, Kane et al. created an animal model where mice that did not experience severe TBI, but rather rmTBI, were evaluated for CTE-like changes [9] . They reported that exposure of mice to single impacts resulted in very mild injury. Mice recovered consciousness spontaneously, showed normal grooming and social interactions with cage mates, and did not display signs of pain or discomfort or resistance to handling after the procedure. Skull fractures, intracranial bleeding, respiratory arrest, or seizures were rarely observed [9] . Therefore, we used the rmTBI model, which may be suitable for evaluating CTE.
Recent observations have indicated that growth hormones and neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), insulin-like growth factor (IGF), and neurotensin, given alone or in combination for spinal cord or brain traumatic injury, can attenuate cord pathology and improve functional outcome and motor paralysis [21] . Cerebrolysin is a mixture of various peptides and neurotrophic factors and plays a clinically proven neuroprotective role in stroke and Alzheimer's disease [19, 26] .
Recently, cerebrolysin, when administered during the early phases of TBI, was reported to confer remarkable neuroprotective effects on brain pathology and sensory-motor functions [23] . Thus, we evaluated the possible neuroprotective role of cerebrolysin in rmTBI, a reliable model of CTE.
Materials and Methods

Experimental Animals and Lesions
Male imprinting control region mice (Samtako, Korea) weighing 23-25 g were used in the present study. Animals were housed in a room under a controlled light/dark cycle (12 h light/12 h dark) at 23°C. Food and water were available ad libitum. All animal-related procedures were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Chungnam National University (CNU-00151). rmTBI animal models were constructed according to a procedure established previously [9] .
Briefly, an iron ball (50 g) was the only material used to impact the mouse skull. The bottom of the weight was The mouse was moved immediately to a holding cage to recover.
Tissue Preparation
To assess the effect of cerebrolysin on rmTBI, mice were administrated 10 μl (1 mg/ml, intra-tail vein) of cerebrolysin (Ever NeuroPharma, Austria) using an insulin syringe. At 4 or 8 weeks after rmTBI with or without cerebrolysin injection ( Fig. 1 ), mice were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally), and perfused transcardially with heparinized phosphate-buffered saline (PBS), followed by perfusion with 4% paraformaldehyde in PBS. Their brains were removed, immersed in the same fixative for 4 h, and then cryoprotected in a 30% sucrose solution.
They were embedded in tissue freezing medium (OCT compound) and then frozen rapidly in 2-methyl butane precooled to its freezing point with liquid nitrogen. Frozen coronal sections (40 μl thick) were obtained using a Leica cryostat. Alternate sections were mounted on gelatin-coated (1:100, #M0701, Dako). Immunohistochemical staining of the tissue sections were performed using the avidin-biotin peroxidase complex (ABC) method described previously [10, 11, 28] . After washing with PBS, tissues were exposed to biotinylated anti-rabbit IgG and streptoavidin peroxidase complex (Vector, USA). Immunostaining was visualized with diaminobenzidine (DAB) and mounted using Polymount (Polysciences, USA).
Image Analysis
To assess the immunohistochemical signals quantitatively, we used the NIH image program (ImageJ) for densitometric measurements. Quantitative data was analyzed using t-test to determine the statistical significance, which was accepted for P values of * < 0.05.
Results
Increases in phospho-tau could be an early sign of CTE, a hallmark neuropathological index that is now being associated with professional athletes exposed to multiple, mild concussive injuries during their careers [15, 18] . Therefore, we evaluated the temporal and cellular pattern of p-tau expression. In group 1, p-tau insulin receptor expression was intense in the deep layer (IV-V) but only occasional in the superficial layer (II-III) of the cortex. In group 2, the p-tau insulin expression pattern was similar to that of group 1, albeit at a lower level. However, p-tau insulin receptor expression peaked in group 3, and then decreased in groups 4 and 5. In the CA1 of the hippocampus after rmTBI, p-tau+ cells were scattered in the stratum oriens (SO), stratum pyramidale (SP), and stratum radiatum (SR) in groups 1 and 3, but were rare in groups 2, 4, and 5. In the DG of the hippocampus after rmTBI, p-tau insulin receptor expression was not found in the granular cell layer (GCL), molecular layer (ML), and subgranular zone (SGZ), except for the hilus.
In the CA3 of the hippocampus after rmTBI, p-tau insulin receptor expression was observed in group 1 but was decreased in group 2. However, p-tau insulin receptor expression was considerable in group 3 but decreased in groups 4 and 5 (A-E4). p-Tau insulin receptor expression in the CA3 showed a punctuate, perinuclear, cytoplasmic distribution (Fig. 2) . Quantitative analysis of p-tau expression after rmTBI with or without cerebrolysin treatment showed significant differences among the CA3 regions (Fig.   3 ).
Because p-tau IR was found in the CA3 region of the hippocampus after rmTBI, we examined whether a selective lesion or neurodegeneration occurred in the CA3 region using cresyl violet staining to assess neuronal survival. In both groups, pyramidal cell degeneration was not found (Fig.   4A ). Next, we evaluated astrocyte and microglia activation after rmTBI with or without cerebrolysin treatment because initial head trauma induces astrocyte and microglial activation, leading to subsequent injury [1] . In groups 2, 4, and 5, GFAP+ astrocytes had tread-like processes and a small cytoplasm. In groups 1 and 3, GFAP+ astrocytes were of mildly activated forms with a hypertrophied cytoplasm and thickened process (Fig. 4B) . However, iba-1+ microglia in both groups had a small cytoplasm and a few thin processes.
Many iba-1+ microglia were not hypertrophied and aggregated in all groups and exhibited s dense cytoplasm and a round morphology, indicating microglia activation (Fig.   4C ). CD45+ macrophages/microglial cells were not observed as activated forms in both groups (Fig. 4D) , suggested that Fig. 2 . p-Tau expression in the cerebral cortex, CA1 region, dentate gyrus, and CA3 region of rmTBI. In group 1, p-tau insulin receptor was expressed intensely in the deep layer (IV-V), and occasionally in the superficial layer (II-III), of the cortex. In group 2, the p-tau insulin receptor expression pattern was similar to that in group 1, albeit at a lower level. However, p-tau insulin receptor expression peaked in group 3, and then decreased in groups 4 and 5 (A-E1). In the CA1 region of the hippocampus after rmTBI, p-tau+ cells were scattered in the stratum oriens (SO), stratum pyramidale (SP), and stratum radiatum (SR) in groups 1 and 3 but was rarely found in groups 2, 4, and 5 (A-E2). In the DG of the hippocampus after rmTBI, p-tau insulin receptor expression was not found in the granular cell layer (GCL), molecular layer (ML), and subgranular zone (SGZ), except for the hilus (A-E3). In the CA3 region of the hippocampus after mTBI, p-tau insulin receptor expression was observed in group 1 but was decreased in group 2. However, p-tau insulin receptor was strongly expressed in group 3, and then was decreased in groups 4 and 4 (A-E4). The rectangular area in A-E4 is a higher magnification view of the CA3 region of each group. p-tau insulin receptor expression in the CA3 region had a punctuate, perinuclear cytoplasmic distribution. Scale bars = 100 μm in A-E and 20 μm in the rectangular area in A-E4.
no infiltration of peripheral macrophages occurred into the brain parenchyma. The latter finding is consistent with previous reports that the rmTBI model used in our study shows a lack of blood-brain barrier disruption and edema [9] .
Quantitative analysis of GFAP expression after rmTBI with or without cerebrolysin treatment showed significant differences among the CA3 regions (Fig. 5 ).
Discussion
An increasingly wide variety of experimental animal models are available to investigate secondary injury processes in TBI and provide preclinical data for candidate therapeutic approaches. Broadly, TBI animal models can be divided into two groups: open head injury (OHI) and closed Fig. 3 . Image analysis of the relative density of p-tau in the cerebral cortex, CA1 region, dentate gyrus, and CA3 region of rmTBI. The data shown are the means ± standard deviation obtained from three independent experiments. *p < 0.05 compared with group 5. Fig. 4 . Cresyl violet staining and GFAP, iba-1, and CD45 expression in the CA3 region of rmTBI. Representative cresyl-violet-stained images showed no pyramidal degeneration or chromatolysis in all groups (A). In groups 2, 4, and 5, GFAP+ astrocytes had tread-like processes and a small cytoplasm. In groups 1 and 3, GFAP+ astrocytes were in a mildly activated form with a hypertrophied cytoplasm and thickened process (B). The rectangular area in B is a higher magnification view of the CA3 region of each group. However, iba-1+ microglia in both groups had a small cytoplasm and a few thin processes. Many iba-1+ microglia were not hypertrophied or aggregated in all groups and exhibited a dense cytoplasm and a round morphology, indicating microglia activation (C). CD45+ macrophages/microglial cells were not observed in an activated form (D). Scale bars = 50 μm in A-D and 20 μm in the rectangular area in B1-4.
head injury (CHI) models. In OHI models, which include the fluid percussion (FP) and controlled cortical impact (CCI) models, the mechanical force is applied directly to the dura mater, which is exposed by a craniotomy. In CHI models, the injury is induced through the intact skull by direct impact (e.g., dropping a weight on the intact skull or striking the intact skull with a piston). Regarding CHI models,
weight-drop models that use the gravitational forces of a free-falling weight have been developed for both rats and mice and are among the simplest and most widely used in TBI research [14] . In the Marmarou method, for example, the rodent's head is supported on a thick block of foam or gel that allows partial head acceleration, causing moderate to severe brain injury with diffuse axon injury [4, 14, 27] .
However, this model is associated with serious outcomes (i.e., high mortality, skull fracture, and respiratory arrest).
To avoid these problems, we used a new murine CHI model (rmTBI), characterized by a completely unrestrained head and body [9] . In this model, the animal is supported by only a sheet of aluminum foil suspended over an empty case with a thick foam pad at the base. The aluminum foil completely tears off during impact, allowing unrestricted head and body movement of the animal as it falls into the cage. These authors reported that mild concussive injury could be repeatedly induced, suggesting that this technique could be used for repeated impacts. We also believe that this model could be suitable for CTE, which is induced by repeated impacts.
As early as 1970, neurofibrillary tangles were reported in the neocortical areas of boxer with CTE [3] . Cortical tangles also constitute a key component of Alzheimer's disease.
However, because they are found in many chronic neurological diseases with different etiologies, they may represent a more general response to neurodegenerative pathology [2] .
Indeed, their abundance in CTE, which is caused by repeated brain trauma episodes, further supports that they may represent a response to brain damage. Tangles are found intracellularly in the cytoplasm of neurons and consist of thread-like aggregates of hyperphosphorylated tau protein [7] . Tau is a normal axonal protein that binds to microtubules via its microtubule-binding domain. Tau is frequently found in a hyperphosphorylated state, and it reduces microtubule binding, causing disassembly of microtubules and leading to compromised neuronal and synaptic function, increased propensity of tau aggregation, and subsequent formation of insoluble fibrils and tangles [13] .
Therefore, phosphorylated tau could be a marker of CTE.
However, identifying tau tangles in the mouse brain by immunohistochemistry is very difficult, but we consistently observe increases in phospho-tau expression after repeated mild head impacts (rmTBI) in mice. In fact, many methods of mild TBI claim to be models of "sports-related" head injury, and they do not cause increases in p-tau expression.
Transgenic mice expressing human tau are interesting, but these mice have some serious problems without head injury so it is hard to judge the exact influence of head impacts on p-tau in their brains [16] . In this study, we confirmed the increase in p-tau expression after rmTBI, suggesting that the rmTBI model is potentially suitable for CTE, because experimental studies in animals suggested that tau phosphorylation may be consequences of repeated brain trauma.
Cerebrolysin is a mixture of neurotrophic factors and peptides that could act in the brain to attenuate oxidative or cellular stress [22, 23] . The reduction in oxidative stress in TBI mediated by cerebrolysin appears to be one of the most important effects of the drug in terms of inducing neuroprotection [8] . In the current study, we found that p-tau expression was decreased in the cortex and CA3 after rmTBI following intra-tail vein injection of cerebrolysin, suggesting that cerebrolysin can confer neuroprotection against the detrimental effects of rmTBI.
Gavett et al. offered a general description of how the damage occurs through the repeated traumatic injury of axons.
Damage to axons affects membrane permeability and causes ionic shifts, resulting in a large influx of calcium. Subsequent release of caspases and calpains would trigger tau phosphorylation, misfolding, shortening, and aggregation, as well as cytoskeleton failure with dissolution of neurofilaments and microtubules [6] . This idea was elaborated from the concept of immunoexcitotoxicity as a possible central mechanism in CTE. Blaylock and Maroon described a cascade of events that begins with an initial head trauma, which "activates" astrocytes and microglia for subsequent injuries [1] .
Therefore, we evaluated astrocyte and microglia activation after TBI with or without cerebrolysin treatment. In the present study, we observed mild astrocyte activation but not microglia activation or infiltration of macrophages into the brain parenchyma, a finding that was consistent with that in a previous study [9] . We also found that astrocyte activation after rmTBI was reduced with cerebrolysin treatment.
One study investigated the effects of cerebrolysin in primary microglial and astrocyte rat cell culture. They showed a pro- genes, chemokines, and other inflammatory mediators in TBI [29] . Therefore, further investigation is warranted regarding whether modulation of this inflammatory response to TBI may have any therapeutic or detrimental effect.
